What's in Prisma Health-Upstate's pipeline?

Prisma Health-Upstate has 8 drugs in our index: 6 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Prisma Health-Upstate's portfolio?

Top competitors by shared drug class: Nova Scotia Health Authority, Assistance Publique - Hôpitaux de Paris, Centre Hospitalier Universitaire de Nīmes, Kuopio University Hospital, Archimedes Development Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/prisma-health-upstate.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Prisma Health-Upstate — Portfolio Competitive Intelligence Brief

Prisma Health-Upstate pipeline: 6 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
AmnioExCel dressing and compression therapy	AmnioExCel dressing and compression therapy	marketed	Biologic wound dressing		Wound Care / Dermatology
Intracervical injection of Vasopressin	Intracervical injection of Vasopressin	marketed	Vasopressor agent	V1 vasopressin receptor	Gynecology
Standard opioid plus methocarbamol	Standard opioid plus methocarbamol	marketed	Opioid analgesic combination with skeletal muscle relaxant	Mu-opioid receptor (opioid component); central nervous system polysynaptic pathways (methocarbamol component)	Pain Management
Liposomal bupivacaine right injection	Liposomal bupivacaine right injection	marketed
Standard Opioid	Standard Opioid	marketed	Opioid analgesic	Mu opioid receptor (primary); delta and kappa opioid receptors (secondary)	Pain Management
Liposomal bupivacaine left injection	Liposomal bupivacaine left injection	marketed	Local anesthetic (amide)	Voltage-gated sodium channels	Anesthesia / Pain Management
Gemcitabine/ clindamycin	Gemcitabine/ clindamycin	phase 3			Oncology

Therapeutic area mix

Pain Management · 2
Anesthesia / Pain Management · 1
Gynecology · 1
Oncology · 1
Wound Care / Dermatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Nova Scotia Health Authority · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Centre Hospitalier Universitaire de Nīmes · 2 shared drug classes
Kuopio University Hospital · 2 shared drug classes
Archimedes Development Ltd · 1 shared drug class
Asbjørn Mohr Drewes · 1 shared drug class
Ain Shams University · 1 shared drug class
Alza Corporation, DE, USA · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Prisma Health-Upstate:

Cite this brief

Drug Landscape (2026). Prisma Health-Upstate — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/prisma-health-upstate. Accessed 2026-05-16.